Peer-influenced content. Sources you trust. No registration required. This is HCN.

Johns Hopkins MedicineWith AI Tool, Johns Hopkins Clinician Boosts Diabetic Retinopathy Screening to 95% Among Pediatric Patients

The Impact of Autonomous AI on Diabetic Retinopathy Screening

In a groundbreaking development for diabetes management, the Food and Drug Administration’s 2018 approval of IDx-DR marks a pivotal moment in medical diagnostics. This autonomous AI-based tool, specifically designed to screen for diabetic retinopathy (DR), represents a significant leap forward in both the efficiency and accessibility of care. Spearheaded by pediatric endocrinologist Risa Wolf at Johns Hopkins, the application of IDx-DR in pediatric settings has not only enhanced screening rates dramatically but has also introduced a new paradigm in the fight against diabetes-related complications in children.

Key Points:

  • FDA Approval: In 2018, IDx-DR became the first autonomous AI-based diagnostic tool approved by the FDA for diabetic retinopathy screening, requiring no doctor interpretation.
  • Pediatric Implementation: Risa Wolf, a pediatric endocrinologist, pioneered the use of IDx-DR for children at Johns Hopkins, significantly increasing access to screenings.
  • Screening Rates Increased: Implementation of IDx-DR in pediatric care settings increased screening rates from 49% to 95%.
  • Cost and Convenience: The use of IDx-DR has resulted in cost savings and added convenience for families requiring diabetic retinopathy screenings.
  • Democratization of Diagnosis: The technology addresses racial bias in diagnosis by using a diverse dataset and a lesion-based algorithm, making it racially invariant.
  • Research on Equitability: Ongoing research aims to determine if IDx-DR can help reduce disparities in diabetic retinopathy screening.

“This AI system has allowed us to improve screening rates for a recommended guideline for kids with diabetes, and it has added convenience and cost savings to families.”
– Risa Wolf, MD, Pediatric Endocrinologist

More on Diabetic Eye Disease (DED)

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form